In that investigation an ML approach allowed identification of a 14-phospoprotein signature associated with EGFR and other relevant cancer signaling pathways including PDK1, caspase-8, Shc, Stat3, p27, GSK-3β, HER3, PKC-α, EGFR, Akt, S6 ribosomal protein, HER3, NF-κB-p65 and Gab-1, potentially able to discriminate tumors sensitive and insensitive to targeted therapy. This evidence concerns the gene NFKB1 and cancer.